Complete Genomics, a life sciences company offering a DNA sequencing platform for human genome sequencing and analysis, announced terms for its IPO on Tuesday. The Mountain View, CA-based company plans to raise $78 million by offering 6 million shares at a price range of $12-$14. At the mid-point of the proposed range, Complete Genomics will command a market value of $390 million. Complete Genomics, which was founded in 2005 and booked $2 million in sales for the 12 months ended June 30, plans to list on the NASDAQ under the symbol GNOM. Its filing follows that of competitor Pacific Biosciences of California, which expects to raise $200 million in its IPO later this week. UBS Investment Bank and Jefferies & Co. are the lead underwriters on the deal, which is scheduled to price during the week of November 8.